Comparison of the Basal Cell Carcinoma (BCC) Tumour Microenvironment to Other Solid Malignancies
Open Access
Abstract
Basal cell carcinoma (BCC) is the most common form of skin cancer, contributing to nearly a third of new cancer cases in Western countries. Most BCCs are considered low risk “routine” lesions that can either be excised through surgery or treated with chemotherapeutic agents. However, around 1–2% of BCC cases are locally aggressive, present a high risk of metastasis, and often develop chemoresistance, termed advanced BCC. There currently exists no animal model or cell line that can recapitulate advanced BCC, let alone intermediate-risk and high-risk early BCC. We previously found that aggressive BCC tumours presented a Th2 cytokine inflammation profile, mesenchymal stem cell properties, and macrophage-induced tumoral inflammation. In this study, we aimed to identify potential BCC “relatives” among solid-organ malignancies who present similar immune cell proportions in their microenvironment compositions. Using immune cell type deconvolution by CIBERSORTx, and cell type enrichment by xCell, we determined three cancers with the most similar tumour microenvironments as compared to BCC. Specifically, chromophobe renal cell carcinoma, sarcoma, and skin cutaneous melanoma presented significance in multiple cell types, namely in CD4+ T lymphocytes, gammadelta T lymphocytes, and NK cell populations. Consequently, further literature analysis was conducted to understand similarities between BCC and its “relatives”, as well as investigating novel treatment targets. By identifying cancers most like BCC, we hope to propose prospective druggable pathways, as well as to gain insight on developing a reliable animal or cell line model to represent advanced BCC.Keywords
Funding Information
- Lady Davis Institute for Medical Research (#312768, #324151, #3253, RRG #4318)
- Jewish General Hospital Foundation (#312768, #324151, #3253, RRG #4318)
- Jewish General Hospital Department of Medicine (#312768, #324151, #3253, RRG #4318)
- Fonds de Recherche du Quebec—Santé (#312768, #324151, #3253, RRG #4318)
- Marathon of Hope Cancer Centre Network—Terry Fox Research Institute (#312768, #324151, #3253, RRG #4318)
- Calcul Québec (#312768, #324151, #3253, RRG #4318)
- Compute Ontario (#312768, #324151, #3253, RRG #4318)
- WestGrid (#312768, #324151, #3253, RRG #4318)
- Compute Canada (#312768, #324151, #3253, RRG #4318)
- Dr. Raymond and Dr. Leora Kahn Research Bursary in Memory of Mrs. Marion Kahn (#312768, #324151, #3253, RRG #4318)
This publication has 61 references indexed in Scilit:
- TERT Promoter Mutations Are Frequent in Cutaneous Basal Cell Carcinoma and Squamous Cell CarcinomaPLOS ONE, 2013
- Highly Recurrent TERT Promoter Mutations in Human MelanomaScience, 2013
- IL-1 and T Helper Immune ResponsesFrontiers in Immunology, 2013
- Efficacy and Safety of Vismodegib in Advanced Basal-Cell CarcinomaNew England Journal of Medicine, 2012
- Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre seriesBJU International, 2011
- Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignanciesBlood, 2011
- Cytogenetics and Molecular Genetics of Myxoid Soft-Tissue SarcomasGenetics Research International, 2011
- Treatment of cutaneous melanoma: current approaches and future prospectsCancer Management and Research, 2010
- Treatment of cutaneous melanoma: current approaches and future prospectsCancer Management and Research, 2010
- Nonmelanoma skin cancer in the United States: IncidenceJournal of the American Academy of Dermatology, 1994